The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Sen. James Lankford has been trying to pass legislation in response to an industry he believes will leave small towns without ...

Unions that provide health benefits to nearly a half-million workers — including many in Ohio — have filed nearly identical ...

Oklahoma's attorney general has accused CVS's Caremark pharmacy benefit manager unit of under-reimbursing pharmacies for ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...

The city of Greensboro has joined a national litigation campaign suing the nation's three largest pharmacy benefit managers and three largest insulin manufacturers with the goal of lowering insulin pr ...

The outgoing Federal Trade Commission chief has listed her ... and two other companies named in the lawsuit—CVS Health's CVS Caremark and Cigna's Express Scripts. Lina Khan, Chair of the Federal ...

UnitedHealth, the biggest insurance company in America, is receiving backlash after an FTC report revealed that it was ...

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.